Nivolumab and total neoadjuvant treatment for locally advanced rectal cancer: results of a phase II trial (CA209-8M4).
BACKGROUND CA209-8M4 is a prospective phase II trial evaluating the addition of nivolumab to total neoadjuvant treatment (TNT) in patients with locally advanced rectal cancer (LARC). MATERIALS AND METHODS Patients with LARC (T3-4Nany or TanyN1) up to 12 cm from the anal verge received standard chemoradiation (CRT) fo...